Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have type 2 diabetes mellitus (T2DM) for at least 6 months~* Have been treated with stable metformin dose for at least 3 months~* Have HbA1c ≥7.5% and ≤11.0% at study entry~* Have body mass index (BMI) ≥25 kilograms per meter squared (kg/m\^2)~Exclusion Criteria:~* Have type 1 diabetes mellitus~* Have used any glucagon-like peptide-1 receptor agonist (GLP-1 RA) or insulin, not including prior short term insulin use (≤14 days)~* Have been taking any other medicine for diabetes (other than metformin) during the last 3 months~* Have used in the last 3 months (or plan to use) prescription weight loss medications~* Have disorders associated with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss~* Current participation in or intent to begin during the study an organized diet and/or exercise weight reduction program (other than the lifestyle and dietary measures for diabetes)~* Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine transaminase (ALT) level \>2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial~* Had chronic or acute pancreatitis any time prior to study entry~* Have had a heart attack or stroke in the past 2 months, or have heart failure that significantly limits their physical activity~* Estimated glomerular filtration rate (eGFR) \<30 milliliters/minute/1.73m\^2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label), calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, as determined by the central laboratory at study entry and confirmed at lead-in~* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2~* Have proliferative retinopathy or maculopathy requiring acute treatment according to the opinion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dulaglutide 1.5 mg (Type: ACTIVE_COMPARATOR): Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.
- Dulaglutide 3 mg (Type: EXPERIMENTAL): Dulaglutide 3 mg administered SC once a week.
- Dulaglutide 4.5 mg (Type: EXPERIMENTAL): Dulaglutide 4.5 mg administered SC once a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).